Acino : appoints Ernesto Alegria as Chief Financial Officer

NEWS RELEASE - PRESSEMITTEILUNG

Alegria as Chief Financial Officer and a Member of Group Management, effective May 1,
2014. In this function he succeeds Runar Bjørklund, who acted as CFO of the Acino Group since January 2014 on an interims basis.
Ernesto Alegria joins the Acino Group from Takeda Pharmaceuticals International GmbH, where he was Head of Business Controlling and Finance for the emerging markets business. Previously, he held increasingly senior financial and commercial roles with Norske Skog and Nycomed Pharma Holding. His professional career began as Finance
Manager with Unilever in Central America. Ernesto Alegria graduated from the University of California Los Angeles (UCLA) with a degree in Economics and Political Science. He also holds a graduate degree in International Relations from the Institut d'Etudes Politiques de Paris in France.
Håkan Björklund, Chairman of Acino Holding AG, said: "Ernesto Alegria brings strong financial, commercial and operations experience at executive level to Acino. In addition, his results orientation, proven execution skills and broad international exposure are well suited to meet the future challenges. We are very pleased that Ernesto Alegria has decided to join our company and we express our sincere thanks to Runar Bjørklund for his support over
the last few months."

Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group is headquartered in Aesch BL.

On December 12, 2013, Pharma Strategy Partners GmbH, a wholly-owned subsidiary of Avista Capital Partners and Nordic Capital, successfully completed its public tender offer for Acino Holding AG. Pharma Strategy Partners GmbH intends to effect a full takeover of Acino, and will delist the Acino shares from the stock exchange.

Robert Schmid

Media & Investor Relations Phone +41 61 338 61 15 robert.schmid@acino-pharma.com

Acino Holding AG

Dornacherstrasse 114

CH-4147 Aesch

Phone +41 61 338 60 00

Fax +41 61 338 60 80 www.acino-pharma.com

distributed by